Holen Sie sich die Stockscreener-App
1.24
1.59%
-0.02
Handel nachbörslich:
1.20
-0.04
-3.23%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BCLI?
Forum
Prognose
Aktiensplit
Brainstorm Cell Therapeutics Inc Aktie (BCLI) Neueste Nachrichten
Stem Cell Therapy Market to Reach $19.1 Billion by 2031 | Advanced - openPR
Brainstorm Cell Therapeutics Inc. (BCLI) Quarterly 10-Q Report - Quartzy
ARMISTICE CAPITAL, LLC Expands Stake in Brainstorm Cell Therapeu - GuruFocus.com
BrainStorm Cell Reports $2.7M Loss, Plans Phase 3b ALS Trial Despite Low Cash | BCLI Stock News - StockTitan
75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - The Malaysian Reserve
BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing - PR Newswire
Amyotrophic Lateral Sclerosis Market Opportunities, - openPR
BrainStorm Teams with Pluri for Key NurOwn ALS Trial Manufacturing Partnership | BCLI Stock News - StockTitan
Amyotrophic Lateral Sclerosis Treatment Market to Grow by USD 663.7 Million from 2024-2028, as Rising Incidence Drives Demand with AI Redefining Market LandscapeTechnavio - The Malaysian Reserve
BrainStorm regains Nasdaq compliance with bid price rule By Investing.com - Investing.com South Africa
BrainStorm regains Nasdaq compliance with bid price rule - Investing.com India
BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - PR Newswire
Neuromuscular Disease Therapeutics Market Statistical - openPR
BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn® Expanded Access Program at 2024 Annual NEALS Meeting - PR Newswire
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Short Interest Update - MarketBeat
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Shares Cross Above 200-Day Moving AverageShould You Sell? - MarketBeat
Amyotrophic Lateral Sclerosis (ALS) Market: Detailed Analysis - openPR
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmBCLI - AsiaOne
Stem Cell Therapy Market Projected to Reach $831.9 Million By 2032 - 대구포스트
Short Interest in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Declines By 91.1% - MarketBeat
Autologous Stem Cell and Non-Stem Cell Based Therapies Industry Report By Type, Application and Geography - Elektrotransports.lv
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated at StockNews.com - MarketBeat
BCLIBrainstorm Cell Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn® Trial at the 2024 Maxim Healthcare Virtual Summit - StockTitan
Gene and Cell Therapies for CNS Disorders Market to Experience - openPR
Brainstorm cell therapeutics CEO acquires $11,308 in stock By Investing.com - Investing.com Canada
Brainstorm cell therapeutics CEO acquires $11,308 in stock - Investing.com
Brainstorm Therapeutics Advances NurOwn® Phase 3b Trials - TipRanks
Brainstorm Cell Therapeutics, Inc. (BCLI) requires closer examination - US Post News
5 Best Stem Cell Companies to Invest In (November 2024) - Securities.io
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Research Coverage Started at StockNews.com - Defense World
Market Momentum: Brainstorm Cell Therapeutics, Inc. (BCLI) Registers a -12.57 Decrease, Closing at 0.22 - The Dwinnex
Brainstorm Cell Therapeutics, Inc. (BCLI) Stock: A Year of Market Fluctuations - The InvestChronicle
The Potential Rise in the Price of Brainstorm Cell Therapeutics, Inc. (BCLI) following insiders activity - Knox Daily
Cell Therapy Technologies Market Size, Product Trends, Key Drivers, Share Analysis And Forecast To 2033 - WhaTech
Brainstorm Cell Therapeutics Stock Scheduled to Reverse Split on Tuesday, October 1st (NASDAQ:BCLI) - Defense World
Cell Theraputics Industry Analysis by Regions, Types and Application - Elektrotransports.lv
BrainStorm announces reverse stock split - Investing.com
Stem Cell Therapy Market Growth, Size, Research Report and Forecast (2024-2034) - 대구포스트
BrainStorm Cell Therapeutics Announces Presentations on NurOwn® at 2024 Annual NEALS Meeting - PR Newswire
Global Stem Cell Therapy Market Set to Reach $ 831.9 Million by 2032 with a 17.2% CAGR GrowthGlobal Stem Cell Therapy Market Set to Reach $ 831.9 Million by 2032 with a 17.2% CAGR Growth - 대구포스트
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Now Covered by Analysts at StockNews.com - Defense World
Cell Theraputics Market 2024-2032 Analysis - Economica
Balance Sheet Insights: Brainstorm Cell Therapeutics, Inc. (BCLI)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
BCLI’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
SEC Form S-3 filed by Brainstorm Cell Therapeutics Inc. - Quantisnow
Brainstorm Cell Therapeutics expands stock incentive plans - Investing.com India
Brainstorm Cell Therapeutics expands stock incentive plans By Investing.com - Investing.com Canada
Brainstorm Cell Therapeutics Enacts Key Corporate Changes - TipRanks
0.93%
3.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):